Department of Gastroenterology, Marmara University, School of Medicine, 34662 Altunizade, Istanbul, Turkey.
Curr Med Chem. 2011;18(5):725-32. doi: 10.2174/092986711794480122.
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has received increased attention. Great efforts are being undertaken to improve the noninvasive diagnosis of NAFLD, with the ultimate goal of optimizing treatment options and clinical outcomes. Research suggests that blood-borne biochemical markers can be used to distinguish simple steatosis from nonalcoholic steatohepatitis (NASH), thus reducing the need of liver biopsy. Future developments in the field of diagnostic biochemistry within the spectrum of NAFLD can make this approach ideal for screening and monitoring purposes. In this review, we provide an overview of the different blood-borne markers which have been recently proposed for differentiating simple steatosis from NASH. We will also consider the practical and statistical issues that seem to be limiting the effective integration of biomarkers into clinical development.
随着肥胖症和糖尿病的持续流行，非酒精性脂肪性肝病（NAFLD）受到了越来越多的关注。人们正在努力提高非酒精性脂肪性肝病的无创诊断水平，最终目标是优化治疗方案和临床结果。研究表明，血液生化标志物可用于区分单纯性脂肪变性和非酒精性脂肪性肝炎（NASH），从而减少肝活检的需要。NAFLD 诊断生物化学领域的未来发展可以使这种方法成为筛查和监测的理想选择。在这篇综述中，我们概述了最近提出的用于区分单纯性脂肪变性和 NASH 的不同血液生化标志物。我们还将考虑似乎限制生物标志物有效纳入临床开发的实际和统计问题。
